Clinical trials are a multi-billion-dollar industry. One of the biggest challenges facing clinical trial research community is satisfying Part 11 Title 21 Code Federal Regulations [ 7 ] and ISO 27789 40 ]. These controls provide audit requirements that guarantee reliability data contained in electronic records. Context-aware smart devices wearable IoT have become increasingly common trials. Ele...

OBJECTIVE The clinical utility of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in the treatment of established human malignancies is limited by the development of resistance to TRAIL. We hypothesized that knockdown of map-kinase activating death domain containing protein (MADD), a TRAIL-resistance factor, may overcome TRAIL resistance in ovarian cancer cells. STUDY DESIGN M...

UNLABELLED Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal cancers, in part, due to resistance to both conventional and targeted therapeutics. TRAIL directly induces apoptosis through engagement of cell surface Death Receptors (DR4 and DR5), and has been explored as a molecular target for cancer treatment. Clinical trials with recombinant TRAIL and DR-targeting agents, however,...

BACKGROUND Several clinical trials indicate that intracoronary radiation is safe and effective for treatment of restenotic coronary arteries. We previously reported 6-month and 3-year clinical and angiographic follow-up demonstrating significant decreases in target lesion revascularization (TLR) and angiographic restenosis after gamma radiation of restenotic lesions. The objective of this study...

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a proapoptotic member of the TNF family of type II membrane proteins, which constitutes one component of T cell cytotoxicity. In this study, we investigated the expression and function of TRAIL in human peripheral blood T (PBT) cells. Although freshly isolated PBT cells did not express a detectable level of TRAIL on their ...

The cytotoxic death ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a tumor-specific agent under development as a novel anticancer therapeutic agent. However, some reports have demonstrated toxicity of certain TRAIL preparations toward human hepatocytes and keratinocytes through a caspase-dependent mechanism that involves activation of the extrinsic death pathway and T...

The randomized clinical trial (RCT) and systematic review underpin evidence-based medicine. They are perceived to provide the strongest evidence on interventions—when viewed as part of an evidence hierarchy, and are generally accepted as such, in clinical medicine. Yet, they are perceived to have limited currency in health promotion practice. Those trying to build bridges across these fields ha...

PURPOSE Several in vitro studies have shown that non-small cell lung cancer (NSCLC) cell lines are sensitive to apoptosis induction by the recombinant human (rh) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death ligand, indicating that rhTRAIL might become an attractive molecule for treatment of NSCLCs. To investigate the therapeutic potential of rhTRAIL, the expression of T...

BACKGROUND AND AIM: Randomized controlled trials (RCTs) are the gold standard for providing evidence in clinical research. The present study was performed with the objective to assess the quality of reports of RCTs in orthodontics in PubMed-indexed journals published by Iranian authors from 2007 to 2017.METHODS: All the articles on orthodontics published from 2007 to 2017 and indexed in PubMed ...

Background Late onset sepsis is a frequent complication of prematurity, associated with increased mortality and morbidity. Probiotics may prevent late onset sepsis in premature infants. The aim of this study was to determine prophylactic effect of oral probiotics in prevention of late onset sepsis of very preterm infants. Materials and Methods This study was a randomized, double blinded, placeb...